Federal official: CDC, FDA taking reports of blood clots and J&J Covid-19 vaccine seriously kvia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kvia.com Daily Mail and Mail on Sunday newspapers.
US health agencies are taking concerns about blood clots and the Johnson & Johnson Covid-19 vaccine "seriously" and are working to assess whether the shot is associated with a very small increased risk of rare blood clots, a federal official told CNN.
Federal official: CDC, FDA taking reports of blood clots and J&J Covid-19 vaccine seriously weny.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from weny.com Daily Mail and Mail on Sunday newspapers.
Early use of therapeutic anticoagulation does not improve survival of critically ill COVID-19 patients
Although abnormal blood clotting has been identified as one of the primary causes of death from COVID-19, early treatment in an intensive care unit (ICU) with therapeutic anticoagulation (anti-clotting) for adults who are critically ill with COVID-19 does not appear to improve chances of survival, and could do more harm than good by increasing the risk for major bleeding, a multicenter research group cautions. In patients critically ill with COVID-19, therapeutic dose anticoagulation started early in the ICU stay was not associated with improved survival, says Hanny Al-Samkari, MD, an investigator in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH) and lead author of a study reporting the findings in the journal
E-Mail
BOSTON - Although abnormal blood clotting has been identified as one of the primary causes of death from COVID-19, early treatment in an intensive care unit (ICU) with therapeutic anticoagulation (anti-clotting) for adults who are critically ill with COVID-19 does not appear to improve chances of survival, and could do more harm than good by increasing the risk for major bleeding, a multicenter research group cautions. In patients critically ill with COVID-19, therapeutic dose anticoagulation started early in the ICU stay was not associated with improved survival, says Hanny Al-Samkari, MD, an investigator in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH) and lead author of a study reporting the findings in the journal